Literature DB >> 11451201

The bleb formation of the extracellular pseudopodia; early evidence of microtubule depolymerization by estramustine phosphate in glioma cell; in vitro study.

D Yoshida1, M Noha, K Watanabe, T Bergenheim, R Henriksson, A Teramoto.   

Abstract

Estramustine phosphate (EMP) is an anti-microtubule agent that depolymerizes microtubules and also causes apoptosis of glioma cells. Both of these pharmacological actions have been previously studied within the same cytotoxic range of EMP concentrations. The purpose of this study was to investigate which of these two phenomena occurred before the other. A preliminary MTT assay was done to distinguish non-cytotoxic (0.005-0.1 microM) and cytotoxic (0.5-10 microM) of EMP for BT4C cells. To investigate apoptotic changes, transmission electron microscopy (TEM), DNA laddering, and in situ endo-labeling (TUNEL) method were employed. A chemotaxis assay was used to assess cell motility. Scanning electron microscopy and TEM immunocytochemistry with an anti-beta tubulin antibody were applied to detect morphological changes of the microtubules. Suppression of cell motility by cytotoxic doses of EMP (0.5-10 microM) group was attributed by the cyto-reductive effect, relating to apoptosis. At 0.01-0.1 microM (non-cytotoxic doses), EMP did not indue apoptosis. At these concentrations, TEM and immunohistochemistry revealed the formation of blebs on the tip of the pseudopodia that contained abnormally depolymerized microtubules, a finding that was not observed at a low temperature or during cell migration. Cell chemotaxis was significantly inhibited by cytostatic EMP doses (0.05 and 0.1 microM). Bleb formation of the pseudopodia might be evidence of the abnormal disassembly of microtubules by cytostatic EMP concentrations, prior to the induction of apoptosis. In glioma cells EMP probably initiates apoptosis by causing the depolymerization of microtubules. Inhibition of cell motility by cytostatic doses of EMP could be beneficial to support other therapies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11451201     DOI: 10.1023/a:1010653613588

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  40 in total

1.  Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53.

Authors:  M Weller; M Trepel; C Grimmel; M Schabet; D Bremen; S Krajewski; J C Reed
Journal:  Neurol Res       Date:  1997-10       Impact factor: 2.448

2.  Estramustine phosphate but not estramustine inhibits the interaction of microtubule associated protein 2 (MAP2) with actin filaments.

Authors:  B Pedrotti; K Islam
Journal:  FEBS Lett       Date:  1997-02-17       Impact factor: 4.124

3.  Distribution of estramustine in the BT4C rat glioma model.

Authors:  M Johansson; A T Bergenheim; R D'Argy; K Edman; P O Gunnarsson; A Widmark; R Henriksson
Journal:  Cancer Chemother Pharmacol       Date:  1998       Impact factor: 3.333

4.  Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action.

Authors:  D Panda; H P Miller; K Islam; L Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

5.  Estramustine binding protein in human brain-tumor tissue.

Authors:  E von Schoultz; T Bergenheim; K Grankvist; R Henriksson
Journal:  J Neurosurg       Date:  1991-06       Impact factor: 5.115

6.  Determinants of human astrocytoma migration.

Authors:  A Giese; M D Rief; M A Loo; M E Berens
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

7.  Alterations in slow transport kinetics induced by estramustine phosphate, an agent binding to microtubule-associated proteins.

Authors:  Z Sahenk; J R Mendell
Journal:  J Neurosci Res       Date:  1992-08       Impact factor: 4.164

8.  In vitro inhibition of cell proliferation, viability, and invasiveness in U87MG human glioblastoma cells by estramustine phosphate.

Authors:  D Yoshida; J M Piepmeier; A Teramoto
Journal:  Neurosurgery       Date:  1996-08       Impact factor: 4.654

9.  Selective antimitotic effects of estramustine correlate with its antimicrotubule properties on glioblastoma and astrocytes.

Authors:  D Yoshida; A Cornell-Bell; J M Piepmeier
Journal:  Neurosurgery       Date:  1994-05       Impact factor: 4.654

10.  Role of microtubules in glucose uptake by C6 glioma cells.

Authors:  S P Singh; Y Gao; L D Singh; S P Kunapuli; R Ravindra
Journal:  Pharmacol Toxicol       Date:  1998-08
View more
  2 in total

Review 1.  Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.

Authors:  Rolf F Barth; Balveen Kaur
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

2.  Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma.

Authors:  Howard Landy; Arnold Markoe; Priscilla Potter; Garrett Lasalle; Angela Marini; Niramol Savaraj; Isildinha Reis; Deborah Heros; Medhi Wangpaichitr; Lynn Feun
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.